Deferiprone, Efficacy and Safety

Indian Journal of Pediatrics

Volumn 71, Issue 3, 2004, Pages 213-216

  Choudhry, V P ^a   Pati, H P ^a   Saxena, Anita ^a   Malaviya, A N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Beta thalassemia; Deferiprone; L1; Oral iron chelator

Indexed keywords

AMOXICILLIN; ANTINUCLEAR ANTIBODY; DEFERIPRONE; FERRITIN; INDOMETACIN; IRON CHELATING AGENT; RHEUMATOID FACTOR;

ADOLESCENT; ANALGESIA; ARTHROPATHY; ARTICLE; BETA THALASSEMIA; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FERRITIN BLOOD LEVEL; HUMAN; INDIA; LEUKOPENIA; MAJOR CLINICAL STUDY; NEUTROPENIA; RESPIRATORY TRACT INFECTION; SEROLOGY;

EID: 1842523243     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02724272     Document Type: Article

References (14)

1. Choudhry VP, Desai N, Pati HP, Nanu A. Current management of homozygous beta thalassemia. Ind Pediatr 1991; 28: 1221-1229.
2. Hoffbrand AV, Wonke B. Iron chelation therapy. J Int Med 1997; 242 (supple 740): 37-41.
3. Graziano, JH, Markenson A. Chelation therapy in Beta Thalassemia Major. Intravenous and sub-cutaneous desferioxamine. J Pediatr 1978; 92: 1278-80.
4. Hussain MAM, Green N, Flynn DM, Hoffbrand AV. Effect of dose, time and ascorbate on iron excretion after subcutaneous desferioxamine. Lancet 1997; 1: 977-979.
5. Cohen A, Schwartz E. Iron chelation therapy with desferioxamine. In Cooley's anemia. J Pediatr 1978; 92: 643-647.
6. Kontoghiorghes GJ. Present status and future prospects of oral iron chelation therapy in thalassemia and other diseases. Ind J Pediatr 1993; 60: 495-507.
7. Agarwal MB, Gupta SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassemia: Indian trial. Br J Hematol 1992; 82: 460-466.
8. Adhikari D, Roy TB, Biswas A, Chakraborty ML, Bhattacharya B, Maitra TK et al. Efficacy and safety of oral iron chelating agent Deferiprone in Beta thalassemia and Hemoglobin E - b thalassemia. Ind Pediatr 1995; 32: 855-861.
9. Mazza P, Amurri G, Lazzari G, Masi C, Palazzo G, Spartera MA, et al. Oral iron chelating therapy. A single center interim report of deferiprone (L1) in thalasslemia. Hematologica 1998; 83: 496-501.
10. Kersten MJ, Lange R, Smeets ME, Vreugdenhil G, Roozendaal KJ, Lameijer W et al. Long term treatment of transfusional iron overload with the oral iron chelator Deferiprone (L1): a Dutch multicenter trial. Annals Hematol 1996; 73: 247-252.
11. Hoffbrand AV, AI Refaic FN, Davis B, Siritanakatkul N, Jackson BF, Cochrane J et al. Long-term of Deferiprone in 51 transfusion dependent iron overloaded patients. Blood 1998; 91: 295-300.
12. Mehta J, Singhal S, Chablani A, Revankar R, Walvalkar A. A1 induced lupus erythematosus. Ind J Hematol Blood Transfusion. 1991; 9: 33-37.
13. Castriota-Scanderberg A, Sacco M. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1. Br J Hematol 1997; 46: 254-255.
14. Loebstein R, Diav-Citrin O, Atanackovic G, Olivieri NF, Koren G. Deferiprone induced agranulocytosis. A critical review of five rechallenged cases. Clin Drug Invest 1997; 13: 345-349.